Stay updated with breaking news from Nasdaq Stro. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sutro Biopharma (NASDAQ:STRO – Get Rating) had its price target lowered by analysts at JMP Securities from $20.00 to $17.00 in a research note issued to investors on Monday, The Fly reports. The brokerage presently has an “outperform” rating on the stock. JMP Securities’ target price would indicate a potential upside of 294.43% from the […]
Sutro Biopharma (NASDAQ:STRO – Get Rating) had its price target trimmed by HC Wainwright from $20.00 to $16.00 in a research note published on Friday, The Fly reports. The firm currently has a buy rating on the stock. Other equities research analysts have also issued research reports about the company. Truist Financial boosted their price […]
Wedbush reissued their outperform rating on shares of Sutro Biopharma (NASDAQ:STRO – Get Rating) in a research report sent to investors on Friday, Benzinga reports. Wedbush currently has a $20.00 price target on the stock. A number of other equities analysts have also recently commented on STRO. Piper Sandler raised their target price on Sutro […]
Sutro Biopharma, Inc. (NASDAQ:STRO – Get Rating) was the target of a significant decline in short interest in March. As of March 15th, there was short interest totalling 1,580,000 shares, a decline of 16.0% from the February 28th total of 1,880,000 shares. Based on an average daily volume of 535,700 shares, the short-interest ratio is […]
- STRO-002 data demonstrating anti-leukemic activity in pediatric patients with relapsed/refractory CBF2AT3-GLIS2 AML are accepted for oral presentation at...